Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia

摘要

Venetoclax in combination with obinutuzumab is an efficacious and tolerable combination that provides a fixed-duration, chemotherapy-free option for patients with previously untreated chronic lymphocytic leukemia (CLL). With the expanding number of therapeutic alternatives available for CLL, discussion of efficacy and potential adverse effects is paramount to formulating the optimal treatment regimen for each individual patient. Many ongoing studies will further define the ideal combination and long-term efficacy of these novel therapies in a prospective manner.